000144977 001__ 144977
000144977 005__ 20240920135617.0
000144977 0247_ $$2doi$$a10.3390/cancers16162798
000144977 0248_ $$2sideral$$a139840
000144977 037__ $$aART-2024-139840
000144977 041__ $$aeng
000144977 100__ $$aSesma, Andrea
000144977 245__ $$aPeripheral Blood TCRß Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer
000144977 260__ $$c2024
000144977 5060_ $$aAccess copy available to the general public$$fUnrestricted
000144977 5203_ $$aThe development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs.
000144977 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00$$9info:eu-repo/grantAgreement/ES/AEI/PTA2019-016739-I$$9info:eu-repo/grantAgreement/ES/AEI/RYC2022-036627-I$$9info:eu-repo/grantAgreement/ES/DGA/B29-20R
000144977 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000144977 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000144977 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julian$$uUniversidad de Zaragoza
000144977 700__ $$aIsla, Dolores
000144977 700__ $$aM. Gálvez, Eva
000144977 700__ $$aGascón-Ruiz, Marta
000144977 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, Luis$$uUniversidad de Zaragoza
000144977 700__ $$aMoratiel, Alba
000144977 700__ $$0(orcid)0000-0002-9600-8116$$aPaño-Pardo, J. Ramón$$uUniversidad de Zaragoza
000144977 700__ $$aQuílez, Elisa
000144977 700__ $$0(orcid)0000-0003-3387-0558$$aTorres-Ramón, Irene
000144977 700__ $$aYubero, Alfonso
000144977 700__ $$aZapata-García, María
000144977 700__ $$aDomingo, María Pilar
000144977 700__ $$aEsteban, Patricia
000144977 700__ $$aSanz Pamplona, Rebeca
000144977 700__ $$aLastra, Rodrigo
000144977 700__ $$0(orcid)0000-0002-3888-7036$$aRamírez-Labrada, Ariel
000144977 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000144977 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000144977 773__ $$g16, 16 (2024), 2798 [22 pp.]$$pCancers$$tCancers$$x2072-6694
000144977 8564_ $$s2160429$$uhttps://zaguan.unizar.es/record/144977/files/texto_completo.pdf$$yVersión publicada
000144977 8564_ $$s2889652$$uhttps://zaguan.unizar.es/record/144977/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000144977 909CO $$ooai:zaguan.unizar.es:144977$$particulos$$pdriver
000144977 951__ $$a2024-09-20-13:01:46
000144977 980__ $$aARTICLE